Quick Answer
Dianthus Therapeutics, Inc. /DE/ reported Operating Income of -$177.93 million for fiscal year 2025.
Dianthus Therapeutics, Inc. /DE/ Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$177.93M | -74.7% |
| 2024 | -$101.86M | -111.5% |
| 2023 | -$48.17M | -62.2% |
| 2022 | -$29.70M | +60.2% |
| 2021 | -$74.69M | +5.1% |
| 2020 | -$78.70M | +5.1% |
| 2019 | -$82.97M | -38.4% |
| 2018 | -$59.96M | -67.8% |
| 2017 | -$35.73M | -285.5% |
| 2016 | -$9.27M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$40.29M | -34.7% | -15.3% |
| June 30, 2025 | -$34.93M | -57.3% | -5.3% |
| March 31, 2025 | -$33.18M | -85.9% | -11.0% |
| September 30, 2024 | -$29.90M | -89.7% | -34.7% |
| June 30, 2024 | -$22.20M | -88.6% | -24.4% |
| March 31, 2024 | -$17.84M | -132.3% | -13.2% |
| September 30, 2023 | -$15.76M | -90.9% | -33.8% |
| June 30, 2023 | -$11.78M | +34.9% | -53.3% |
- Dianthus Therapeutics, Inc. /DE/ showed a decrease of -74.7% in Operating Income compared to the prior fiscal year.
- Over the 2016–2025 period, Dianthus Therapeutics, Inc. /DE/’s operating income has declined by 1819.9% (from -$9.27 million to -$177.93 million).
- The most recent figure is from Dianthus Therapeutics, Inc. /DE/’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 9, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: